Daily Respiratory Research Analysis
Three impactful respiratory studies span basic-to-clinical translation: (1) an epigenetic mechanism in pulmonary fibrosis where KMT2A drives fibroblast PU.1 via H3K4me3 and is druggable; (2) a randomized trial in Kyrgyzstan showing point-of-care CRP testing safely cuts pediatric antibiotic use for acute respiratory infections; and (3) epigenetic age acceleration predicts survival and mediates PM2.5 exposure effects in fibrotic interstitial lung disease.
Summary
Three impactful respiratory studies span basic-to-clinical translation: (1) an epigenetic mechanism in pulmonary fibrosis where KMT2A drives fibroblast PU.1 via H3K4me3 and is druggable; (2) a randomized trial in Kyrgyzstan showing point-of-care CRP testing safely cuts pediatric antibiotic use for acute respiratory infections; and (3) epigenetic age acceleration predicts survival and mediates PM2.5 exposure effects in fibrotic interstitial lung disease.
Research Themes
- Epigenetic drivers and targets in pulmonary fibrosis
- Point-of-care diagnostics for antimicrobial stewardship in respiratory infections
- Environmental epigenetics and prognosis in interstitial lung disease
Selected Articles
1. Histone methyltransferase KMT2A promotes pulmonary fibrogenesis via targeting pro-fibrotic factor PU.1 in fibroblasts.
This mechanistic study identifies KMT2A as an epigenetic driver of pulmonary fibrosis that upregulates PU.1 in fibroblasts via H3K4me3, thereby promoting fibrogenesis. Genetic knockdown, fibroblast-specific PU.1 deletion, and a KMT2A complex inhibitor (mm102) each attenuated bleomycin-induced fibrosis, nominating KMT2A→PU.1 as a targetable axis.
Impact: Reveals a previously unrecognized epigenetic pathway driving IPF and provides pharmacologic proof-of-concept for targeting KMT2A. This could reorient antifibrotic drug discovery toward histone-modifying enzymes.
Clinical Implications: Although preclinical, the data suggest KMT2A inhibition could complement current antifibrotics and that PU.1/H3K4me3 signatures may serve as biomarkers for patient stratification.
Key Findings
- KMT2A-positive fibroblasts are increased in IPF lungs and in bleomycin-injured mouse lungs.
- Fibroblast KMT2A knockdown and the KMT2A complex inhibitor mm102 attenuate bleomycin-induced pulmonary fibrosis.
- KMT2A upregulates PU.1 via H3K4me3 at the PU.1 promoter; fibroblast-specific PU.1 knockout reduces fibrosis.
Methodological Strengths
- Convergent validation across human IPF tissues, in vivo mouse models, and primary fibrotic fibroblasts
- Genetic (AAV6 knockdown, fibroblast-specific knockout) and pharmacologic (mm102) interventions with mechanistic assays (H3K4me3 at PU.1 promoter)
Limitations
- Bleomycin models may not fully recapitulate chronic human IPF pathobiology
- Selectivity and translational pharmacology of mm102 require further characterization
Future Directions: Develop selective KMT2A inhibitors with favorable PK/PD; validate PU.1/H3K4me3 signatures and KMT2A activity in longitudinal human IPF cohorts; assess combinatorial therapy with approved antifibrotics.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fibrotic disease driven by both environmental and genetic factors. Epigenetics refers to changes in gene expression or cellular phenotype that do not involve alterations to DNA sequence. KMT2A is a member of the SET family which catalyses H3K4 methylation. RESULTS: Through microarray and single-cell sequencing data, we discovered KMT2A-positive fibroblasts were increased in IPF lung tissues. KMT2A level was increased in IPF and bleomycin-induced pulmonary fibrosis mice lung tissues collected in our centre. Mice with AAV6-induced KMT2A knockdown in fibroblast showed attenuated pulmonary fibrosis after bleomycin treatment. Bioinformation also revealed that transcription factor PU.1 was a target of KMT2A. We demonstrated that PU.1 levels were increased in IPF tissues, bleomycin-induced mice lung tissues and primary fibrotic fibroblasts. KMT2A knockdown decreases PU.1 expression in vitro while KMT2A overexpression induces PU.1 activation. PU.1 fibroblast-specific knockout mice showed attenuated lung fibrosis induced by bleomycin. Furthermore, we demonstrated KMT2A up-regulated PU.1 in fibroblasts by catalysing H3K4me3 at the promoter of the PU.1 gene. The KMT2A transcription complex inhibitor mm102 treatment attenuated bleomycin-induced pulmonary fibrosis. CONCLUSION: The current study indicated that histone modification participates in the pathogenesis of IPF and KMT2A may have the potential to be a therapeutic target of IPF treatment. KEY POINTS: KMT2A plays a role in pulmonary fibrogenesis. KMT2A regulates PU.1 transcription in fibroblasts through H3K4me3 at promoter. KMT2A inhibitor attenuates pulmonary fibrosis in mice.
2. Accelerated epigenetic ageing worsens survival and mediates environmental stressors in fibrotic interstitial lung disease.
Across two fILD cohorts, epigenetic age acceleration exceeded chronological age by a median of 11.7 years, associated with worse survival. Ambient PM2.5 exposure related to poorer outcomes, with epigenetic age acceleration statistically mediating adverse exposure effects.
Impact: Links a modifiable environmental exposure to biologic ageing and prognosis in fILD, integrating environmental health and epigenetics and suggesting biomarker-guided risk stratification.
Clinical Implications: Epigenetic age measures could refine prognostication and identify patients most susceptible to environmental harms, supporting exposure mitigation and personalized follow-up strategies.
Key Findings
- Median epigenetic age in fILD exceeded chronological age by 11.7 years.
- Higher PM2.5 exposure associated with worse survival in combined cohort analyses.
- Epigenetic age acceleration statistically mediated the adverse impact of PM2.5 on outcomes.
Methodological Strengths
- Multicentre international cohorts with replication across sites
- Use of mediation analysis linking exposure, epigenetic ageing, and survival
Limitations
- Observational design with potential residual confounding
- Exposure estimates based on ambient PM2.5 rather than personal monitoring
Future Directions: Prospective validation of epigenetic clocks as prognostic tools; interventional studies testing whether exposure reduction modifies epigenetic ageing and outcomes.
BACKGROUND: The role of epigenetic ageing in the environmental pathogenesis and prognosis of fibrotic interstitial lung disease (fILD) is unclear. We evaluated whether ambient particulate matter with diameter ≤2.5 μm (PM METHODS: This multicentre, international, cohort study included patients with fILD from the University of Pittsburgh (UPitt, n=306) and University of British Columbia (UBC, n=170). 5-year PM RESULTS: Median epigenetic age was 11.7 years older than chronological age in patients with fILD. In combined cohort analysis, each interquartile range (IQR) increase in PM CONCLUSIONS: Epigenetic age acceleration is associated with worse survival and mediates adverse exposure impacts in fILD.
3. C-reactive protein testing in primary care and antibiotic use in children with acute respiratory tract infections in Kyrgyzstan: an open-label, individually randomised, controlled trial.
In a randomized primary care trial (n=1204), point-of-care CRP testing reduced antibiotic prescribing in children with acute respiratory infections by 24 percentage points versus usual care without prolonging recovery or increasing hospitalizations. Reconsultations were modestly higher in the CRP arm.
Impact: Provides high-quality evidence from an LMIC setting that CRP-guided care safely reduces pediatric antibiotic use for respiratory infections, directly informing antimicrobial stewardship policy.
Clinical Implications: Adopting CRP point-of-care testing in pediatric ARTI triage can curb unnecessary antibiotics without compromising safety; systems should prepare for slightly increased reconsultations.
Key Findings
- CRP testing reduced antibiotic use from 60% to 36% (risk difference 24 percentage points; 95% CI 15–34).
- No difference in time to recovery or hospitalizations between groups; safety preserved.
- Reconsultation rates were modestly higher with CRP testing (OR 1.31; 95% CI 1.01–1.71).
Methodological Strengths
- Individually randomized controlled design with blinded follow-up assessments
- Large sample size in real-world primary care across a resource-limited setting
Limitations
- Open-label intervention for clinicians may introduce performance bias
- Conducted in a single country; generalizability to other health systems requires validation
Future Directions: Cost-effectiveness analyses, implementation research on workflow integration and caregiver communication, and multicountry trials to assess generalizability.
BACKGROUND: Addressing the global antibacterial resistance crisis and aligning with the Kyrgyz Ministry of Health's research priorities, this study assesses the efficacy and safety of C-reactive protein (CRP) testing to guide antibiotic prescriptions in children with acute respiratory tract infections (ARTI) in Kyrgyzstan. METHODS: In this open label individually randomised controlled trial, children aged 6 months to 12 years with ARTI in primary care settings were assigned to receive either standard care or standard care plus CRP testing. The study measured two primary outcomes: total antibiotic usage over a 14-day follow-up and caregiver-reported time to recovery. Follow-up assessments (days 3, 7, 14) were blinded. Trial registration: NCT05195866. FINDINGS: A total of 1204 patients were randomised. Antibiotic use was lower in the CRP group (216/601, 36%) compared to the control group (362/603, 60%; Risk difference: 24 percentage points; 95% confidence interval (CI): 15-34). There was no significant difference in time to recovery (log-rank test p = 0.090) and the prespecified non-inferiority margin of one day was not exceeded. Hospital admissions were similar in both groups (CRP: 31 (5%), control: 26 (4%); odds ratio (OR) 1.20, 95% CI 0.69-2.10), but the CRP group re-consulted more often (OR 1.31, 95% CI 1.01-1.71) during the 14 days of follow-up. INTERPRETATION: Implementing CRP testing in primary care for paediatric ARTI in Kyrgyzstan significantly reduced antibiotic use without negative effects on safety, supporting its role in national antimicrobial stewardship strategies. FUNDING: International Centre for Antimicrobial Resistance Solutions (ICARS).